Wegovy pill weight loss infographic showing 6.2% average loss in 5,872 real-world patients

Real-world Wegovy pill weight loss data released on November 14, 2026 show that 5,872 US adults who stayed on Novo Nordisk’s once-daily oral semaglutide for three months lost an average of 6.2% of their body weight, about 6.3 kg (13.9 lb) from an average starting weight of 103 kg. The analysis, drawn from patients on the Ro telehealth platform and due for presentation at ObesityWeek 2026 in Washington, is the first large look at how the pill performs outside a clinical trial since its US launch in January.

Key takeaways on Wegovy pill weight loss

  • Average weight loss was 6.2% at three months among people who kept taking the pill.
  • About three in five lost at least 5% of body weight, and roughly one in six lost at least 10%.
  • The result is in line with, and slightly above, the 5.5% seen at 12 weeks in Novo’s late-stage trial.
  • Only people who stayed on treatment for the full three months were counted, so the figure does not capture those who stopped early.
  • In longer trials, oral Wegovy produced about 14% weight loss over 64 weeks; three months is early in that curve.

Who was studied and how

According to Reuters, the dataset included adults on Ro who had never used a weight-loss medicine before and who started the Wegovy pill between January 5 and February 7, 2026. Everyone counted stayed on the drug for the full three months. That design answers a practical question many people ask before starting: if I take it as prescribed, what can I expect in the first quarter?

It does not answer a second, equally important question: how many people stop. Real-world GLP-1 studies often find meaningful drop-off in the first months because of nausea, cost or supply. Because the Ro analysis was restricted to people who continued, the 6.2% figure is best read as a ceiling for early results rather than an average for everyone who fills a first prescription.

The numbers at a glance

MeasureResult
Patients analysed5,872 adults, new to weight-loss drugs
Start window5 January to 7 February 2026
Average baseline weight103.0 kg (227 lb)
Average weight lost at 3 months6.3 kg (13.9 lb), or 6.2%
Lost at least 5%About 3 in 5 (roughly 3,500 people, by our calculation)
Lost at least 10%About 1 in 6 (roughly 980 people, by our calculation)
Trial comparison at 12 weeks5.5% in Novo’s late-stage study
Source: Novo Nordisk real-world data reported by Reuters, 14 Nov 2026.

How the pill compares with injections and Lilly’s Foundayo

The Wegovy pill contains semaglutide, the same GLP-1 drug in Ozempic and Wegovy injections, at a higher oral dose because only a small share is absorbed through the stomach. It has to be taken on an empty stomach with a little water, followed by a wait before eating. In trials, oral Wegovy led to roughly 14% weight loss over 64 weeks. Eli Lilly’s Foundayo (orforglipron), a non-peptide GLP-1 pill that can be taken without food restrictions, produced about 11% over 72 weeks in its own studies. These come from separate trials with different populations, so they are not a head-to-head comparison.

Novo’s chief scientific officer Martin Holst Lange described the real-world findings as encouraging because they broadly reproduce the trial result. Novo says oral treatments now make up about a third of US obesity prescriptions and that it holds more than 80% of new oral prescriptions, though Lilly’s pill is competing hard. Lilly’s convenience pitch was on show at the same meeting, where a survey found 96% to 98% of Foundayo users called the pill simple to take. For background on that race, see our report on orforglipron’s approval in China.

Why telehealth data matter here

The source of the data is itself part of the story. A large share of US obesity prescribing now runs through direct-to-consumer telehealth companies such as Ro, which can track dosing and weight remotely at scale. Acumen Research and Consulting valued the global digital health for obesity market at USD 48.1 billion in 2023 and projects it to reach USD 276.5 billion by 2032, a CAGR of 21.7%. Acumen found services to be the largest segment and Asia-Pacific the fastest-growing region, which is relevant as Indian telehealth players expand weight-management offerings.

Self-reported weights on a telehealth platform are less controlled than clinic weigh-ins, and patients who choose a cash-pay digital service may differ from the wider population. Those limits do not make the data meaningless, but they are worth keeping in mind until the full ObesityWeek presentation and any peer-reviewed paper are available.

What it means for readers in India

Oral semaglutide has been sold in India for type 2 diabetes as Rybelsus, and Indian drugmakers are now producing generic semaglutide for export markets, as our coverage of Aspen’s India-made generic semaglutide shows. The higher-dose Wegovy pill for weight loss is a separate product, and these US results do not change its regulatory status in India. Anyone considering a GLP-1 medicine should do so under a doctor’s supervision, since dosing, side effects and suitability vary by person. More updates are in our Pharmaceutical news section.

What to watch

Key gaps include how many Ro patients stopped before three months, what doses people reached, side-effect rates, and whether weight loss keeps tracking the trial curve at six and twelve months. Novo previously reported that people who switched from injections to the pill continued to lose weight; longer real-world follow-up will test whether that holds across larger groups.

FAQ

How much weight can you lose on the Wegovy pill in 3 months?

In this real-world analysis of 5,872 people who stayed on it, the average was 6.2% of body weight, about 6.3 kg. Individual results varied: about one in six lost 10% or more.

Is the Wegovy pill as effective as the injection?

In its trials, oral Wegovy produced about 14% weight loss over 64 weeks, broadly similar to injectable semaglutide. No large head-to-head real-world comparison has been published yet.

Is the Wegovy pill better than Foundayo?

They have not been compared directly. In separate trials, oral Wegovy showed about 14% weight loss at 64 weeks and Foundayo about 11% at 72 weeks, but Foundayo does not require fasting before each dose.

Is the Wegovy pill available in India?

Oral semaglutide is sold in India for diabetes as Rybelsus. Check with your doctor or pharmacist for the current status of the higher-dose weight-loss version.

Sources: Novo Nordisk real-world data via Reuters (14 Nov 2026), CTV News, Eli Lilly ObesityWeek release. Market data: Acumen Research and Consulting, Digital Health for Obesity Market report. Not medical advice; do not change medication without consulting a doctor. Last updated: 15 November 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

One thought on “Wegovy Pill Weight Loss: Real-World Users Lose 6.2% in Three Months”

Leave a Reply

Your email address will not be published. Required fields are marked *